EHAM
REGN icon

Eagle Harbor Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eagle Harbor Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-347
Closed -$205K – 107
2022
Q2 		$205K Hold
347
– – 0.32% 98
2022
Q1 		$242K Buy
+347
New +$220K 0.31% 92

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Eagle Harbor Asset Management's REGN Position: Q3 2022 in Review

Eagle Harbor Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 347 shares — an estimated $205K sold.

Eagle Harbor Asset Management first reported a position in REGN in Q1 2022 and held it in 2 quarters. The position peaked at $242K in Q1 2022. 1,081 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Eagle Harbor Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Eagle Harbor Asset Management sold 347 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $205K.
  • Eagle Harbor Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Eagle Harbor Asset Management's Regeneron Pharmaceuticals position peaked at $242K in Q1 2022.
  • 1,081 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Eagle Harbor Asset Management's 13F filing for Q3 2022, filed 11 Aug 2026.